AGTC
$5.40
Applied Genetic Tech
$.28
5.47%
AGTC
Earnings Whisper ®
N/A
2nd Quarter December 2019
Consensus:  ($0.59)
Revenue:  $0.00 Mil
Thursday
Feb 6
4:00 PM ET
Score
Grade
Tweet Share Watch
Tweet Share Watch

What do you expect when AGTC reports earnings?
Beat
Meet
Miss

Where is AGTC's stock price going from here?
Up
Flat
Down
Stock chart of AGTC
Analysts
Summary of analysts' recommendations for AGTC
Score
Grade
Pivots
Resistance
$5.43
$5.34
$5.23

$5.14

Support
$5.03
$4.94
$4.83
Tweet
Growth
Description
Applied Genetic Technologies Corporation is a clinical-stage biotechnology company. It develops gene therapy products for inherited orphan ophthalmology diseases. Its lead product candidates in the preclinical stage include treatments for X-linked retinoschisis, Achromatopsia, and X-linked retinitis pigmentosa, which are diseases of the eye caused by mutations in single genes. Applied Genetic Technologies Corporation is headquartered in Alachua, Florida.
Peers
BiogenAmgenGilead SciencesNeurocrine BiosciencesBluebird BioSeattle GeneticsQiagen N.V.RepligenBioCryst PharmaceuticalsNovavax